Th17 cells: A new therapeutic target in inflammatory dermatoses

被引：59

作者：

Asarch, Adam ^{[1
]}

Barak, Orr ^{[1
]}

Loo, Daniel S. ^{[1
]}

Gottlieb, Alice B. ^{[1
]}

机构：

[1] Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2008年 / 19卷 / 06期

关键词：

Autoimmune disease; biologic therapy; cutaneous immunology; IL-17; IL-22; IL-23; inflammatory dermatoses; psoriasis; Th17; cells;

D O I：

10.1080/09546630802206660

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 [皮肤病与性病学];

摘要：

Th17 cells, named for their secretion of interleukin-17 (IL-17), are a new class of T-cells involved in a wide range of cutaneous autoimmune and inflammatory conditions. An overactive Th17 cell response in the skin can produce damaging results. There appears to be a partial role for the Th17 axis in the pathogenesis of a range of dermatological diseases including allergic contact dermatitis, atopic dermatitis, psoriasis, and scleroderma. Immunologists have also discovered a unique association between Th17 cells and cutaneous T-cell lymphoma. The Th17 branch has been linked to a number of additional systemic inflammatory diseases with significant cutaneous pathology such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and Behcet's disease. Newly developed treatment modalities for neutralizing the Th17 branch of the immune system are proving to be valuable additions to the current therapeutic armamentarium.

引用

页码：318 / 326

页数：9

共 87 条

[1]

Abramovits W, 2005, J AM ACAD DERMATOL, V53, pS86, DOI 10.1016/j.jaad.2005.04.034

[2]

Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin-4-induced activation of human keratinocytes [J].

Albanesi, C ;

Scarponi, CS ;

Cavani, A ;

Federici, M ;

Nasorri, F ;

Girolomoni, G .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (01) :81-87

[3]

Albanesi C, 1999, J IMMUNOL, V162, P494

[4]

[Anonymous], HARRISONS PRINCIPLES

[5]

ASARCH A, 2008, J DERMATOLO IN PRESS

[6]

TGF-β1 gene polymorphism in psoriasis vulgaris [J].

Baran, Wojcech ;

Szepietowski, Jacek C. ;

Mazur, Grzegorz ;

Baran, Eugeniusz .

CYTOKINE, 2007, 38 (01) :8-11

[7]

Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism [J].

Benchetrit, F ;

Ciree, A ;

Vives, V ;

Warnier, G ;

Gey, A ;

Sautès-Fridman, C ;

Fossiez, F ;

Haicheur, N ;

Fridman, WH ;

Tartour, E .

BLOOD, 2002, 99 (06) :2114-2121

[8]

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes [J].

Cargill, Michele ;

Schrodi, Steven J. ;

Chang, Monica ;

Garcia, Veronica E. ;

Brandon, Rhonda ;

Callis, Kristina P. ;

Matsunami, Nori ;

Ardlie, Kristin G. ;

Civello, Daniel ;

Catanese, Joseph J. ;

Leong, Diane U. ;

Panko, Jackie M. ;

McAllister, Linda B. ;

Hansen, Christopher B. ;

Papenfuss, Jason ;

Prescott, Stephen M. ;

White, Thomas J. ;

Leppert, Mark F. ;

Krueger, Gerald G. ;

Begovich, Ann B. .

AMERICAN JOURNAL OF HUMAN GENETICS, 2007, 80 (02) :273-290

[9]

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris [J].

Chamian, F ;

Lowes, MA ;

Lin, SL ;

Lee, E ;

Kikuchi, T ;

Gilleaudeau, P ;

Sullivan-Whalen, M ;

Cardinale, I ;

Khatcherian, A ;

Novitskaya, I ;

Wittkowski, KM ;

Krueger, JG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (06) :2075-2080

[10]

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis [J].

Chan, Jason R. ;

Blumenschein, Wendy ;

Murphy, Erin ;

Diveu, Caroline ;

Wiekowski, Maria ;

Abbondanzo, Susan ;

Lucian, Linda ;

Geissler, Richard ;

Brodie, Scott ;

Kimball, Alexa B. ;

Gorman, Daniel M. ;

Smith, Kathleen ;

Malefyt, Rene de Waal ;

Kastelein, Robert A. ;

McClanahan, Terrill K. ;

Bowman, Edward P. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (12) :2577-2587

← 1 2 3 4 5 6 7 8 9 →